Ruconest (C1 esterase inhibitor, recombinant) is a brand-name drug prescribed to treat acute episodes of hereditary angioedema in adults and some children. It’s given as an intravenous (IV) injection ...

Ruconest can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects last longer than that ...

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. SAN DIEGO, CA and LEIDEN, THE NETHERLANDS--(Marketwire - Nov 7, 2012) - Statistically ...

Ruconest (C1 esterase inhibitor, recombinant) can cause side effects that range from mild to serious. More common side effects include headache and nausea. If side effects from Ruconest become ...

If you have heard of Ruconest, but you’re not sure what it is, then keep reading! Ruconest is an entirely manmade type of protein known as a C1 esterase inhibitor. C1 esterase inhibitor naturally ...

The US Food and Drug Administration (:FDA) recently accepted the Biologics License Application (:BLA) for Santarus, Inc. (SNTS) and partner, Pharming Group NV’s Ruconest. The companies are looking to ...

The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE). The FDA asked Pharming ...

Santarus and Pharming Group NV announced that their pivotal Phase 3 clinical study to evaluate the safety and efficacy of the investigational drug Ruconest (recombinant human C1 esterase inhibitor) ...

Santarus and Pharming Group NV announced that the FDA has accepted for filing the Biologics License Application (BLA) for the investigational drug Ruconest (INN conestat alfa) 50 IU/kg for the ...

US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis in patients with hereditary angioedema (HAE). US regulators have turned down ...

LEIDEN, THE NETHERLANDS--(Marketwire - Mar 28, 2013) - Leiden, the Netherlands, March 28th, 2013. Biotech company Pharming Group NV ("Pharming") (EURONEXT BRUSSELS: PHARM) announced today that it has ...